Company Overview
aTyr Pharma, Inc. operates as a clinical stage biotechnology firm focused on the discovery and development of product candidates that translate tRNA synthetase biology into new therapies targeting fibrosis and inflammation within the United States. The company functions within the broader healthcare sector and specifically the biotechnology industry, positioning itself to develop treatments for conditions where traditional therapies may be limited. This biotechnology entity maintains a market capitalization of $73.73M and reports annual revenue of $190,000 for the trailing twelve months, while employing a workforce of 58 individuals. These financial figures indicate that the company operates on a micro-cap scale with minimal current revenue generation, suggesting that its primary value proposition relies on the potential future success of its pipeline rather than existing commercial sales or established market share.
Financial Health
The company reported revenue of $190,000, net income of $-74,118,000, and EBITDA of $-76,963,000 for the trailing twelve months. The substantial gap between the nominal revenue of $190,000 and the significant net loss of $-74.118M reveals a cost structure where operating expenses vastly outweigh any current income, which is typical for early-stage biotechnology firms investing heavily in research and development. Free cash flow stands at $-33,797,876, indicating that the company is currently burning cash to fund its operations and development programs, thereby limiting immediate financial flexibility without external capital injections. Analysis of the margins shows a gross margin of 0.0%, an operating margin of -40856.3%, and a profit margin of 0.0%, highlighting that the company has not yet achieved profitability on a per-unit basis and is operating at a significant loss relative to its sales. On the balance sheet, the company holds $78.69M in cash against $12.03M in debt, resulting in a debt-to-equity ratio of 17.88, which suggests a leveraged position where equity is significantly smaller than total debt obligations. Despite the high debt-to-equity ratio, the current ratio of 5.30 indicates strong short-term liquidity, as the company possesses more than five times the current assets necessary to cover its current liabilities. Return on Equity is -108.1% and Return on Assets is -51.1%, metrics that reveal that management effectiveness is currently measured by the depletion of shareholder value and asset base to fund long-term development rather than generating immediate returns.
Valuation Assessment
The trailing twelve-month P/E ratio is not applicable due to the lack of positive earnings, while the forward P/E is listed as -1.87, a metric that implies the market is pricing in continued losses or expects a turnaround that has not yet materialized in reported earnings. The price-to-book ratio stands at 1.09, indicating that the market values the company at a slight premium over its book value, suggesting confidence in the potential of its intangible assets and pipeline despite current financial losses. Alternative valuation metrics such as a price-to-sales ratio of 388.08 and an EV/EBITDA of -0.09 suggest that the stock is priced primarily on its potential future commercialization rather than current financial performance, as the high multiple reflects the speculative nature of clinical-stage assets. The 52-week high is $7.29 and the 52-week low is $0.64, meaning the current trading price sits at a level that reflects significant volatility within this wide range over the past year. The beta value of 0.56 indicates that the stock price exhibits lower volatility relative to the broader market, moving at a slower pace than the general equity index during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning there is no historical comparative data available to determine the rate at which earnings are growing relative to revenue. Because the company reports a net income of $-74,118,000 and does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the firm retains all earnings to reinvest into its growth initiatives rather than distributing cash to shareholders. As a non-dividend payer, aTyr Pharma reinvests its limited financial resources and available cash reserves directly into the discovery and development of its product candidates to advance its pipeline toward clinical trials or commercial launch. The overall growth and income profile is characterized by a complete absence of current income generation and undefined growth rates, relying entirely on the successful translation of tRNA synthetase biology into marketable therapies for fibrosis and inflammation.